MetaVia banks 2027 plans on $12.6m cash as it eyes FDA talks on liver combination

MetaVia's latest corporate presentation sets out a development schedule that runs into the second half of 2027. The company reported cash of $12.6 million at 30 June 2026, the most recent balance in the material. Any partner or financier weighing the plan will want to know how far that sum goes, and the presentation as summarised does not say.

The commercial case rests on two clinical-stage assets. For DA-1726, MetaVia cites interim data from Part 3B of its study showing liver fat down by roughly 68% by day 109. For vanoglipel, it points to lower alanine aminotransferase (ALT), a liver enzyme marker, in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a Phase 2a study. No ALT magnitudes or study design details are given in the material, and the DA-1726 figure is interim, company-reported data that has not been peer reviewed.

The next step is regulatory. MetaVia says it intends to meet the US Food and Drug Administration in the second half of 2026 to discuss using vanoglipel alongside resmetirom. A Phase 2a combination study is pencilled in for the first half of 2027, and the agency's feedback is likely to shape its design. The company has not disclosed the outcome of any such meeting.

Further out, MetaVia plans a Phase 2 trial of DA-1726 in metabolic dysfunction and alcohol-related liver disease (MetALD) and in alcohol-related liver disease (ALD), slated for the second half of 2027. That would extend the pipeline beyond MASH, an indication where, as general industry context, many developers are active. The presentation does not provide trial costs or funding sources for either study.